Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours
65
Zitationen
24
Autoren
2021
Jahr
Abstract
AIM: Sentinel lymph node status is a central prognostic factor for melanomas. However, the surgical excision involves some risks for affected patients. In this study, we therefore aimed to develop a digital biomarker that can predict lymph node metastasis non-invasively from digitised H&E slides of primary melanoma tumours. METHODS: A total of 415 H&E slides from primary melanoma tumours with known sentinel node (SN) status from three German university hospitals and one private pathological practice were digitised (150 SN positive/265 SN negative). Two hundred ninety-one slides were used to train artificial neural networks (ANNs). The remaining 124 slides were used to test the ability of the ANNs to predict sentinel status. ANNs were trained and/or tested on data sets that were matched or not matched between SN-positive and SN-negative cases for patient age, ulceration, and tumour thickness, factors that are known to correlate with lymph node status. RESULTS: The best accuracy was achieved by an ANN that was trained and tested on unmatched cases (61.8% ± 0.2%) area under the receiver operating characteristic (AUROC). In contrast, ANNs that were trained and/or tested on matched cases achieved (55.0% ± 3.5%) AUROC or less. CONCLUSION: Our results indicate that the image classifier can predict lymph node status to some, albeit so far not clinically relevant, extent. It may do so by mostly detecting equivalents of factors on histological slides that are already known to correlate with lymph node status. Our results provide a basis for future research with larger data cohorts.
Ähnliche Arbeiten
Dermatologist-level classification of skin cancer with deep neural networks
2017 · 13.437 Zit.
Tumor Angiogenesis: Therapeutic Implications
1971 · 10.108 Zit.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
2011 · 7.668 Zit.
Pembrolizumab versus Ipilimumab in Advanced Melanoma
2015 · 5.803 Zit.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2017 · 5.354 Zit.
Autoren
- Titus J. Brinker
- Lennard Kiehl
- Max Schmitt
- Tanja Jutzi
- Eva Krieghoff‐Henning
- Dieter Krahl
- Heinz Kutzner
- Patrick Gholam
- Sebastian Haferkamp
- Joachim Klode
- Dirk Schadendorf
- Achim Hekler
- Stefan Fröhling
- Jakob Nikolas Kather
- Sarah Haggenmüller
- Christof von Kalle
- Markus V. Heppt
- Franz J. Hilke
- Kamran Ghoreschi
- Markus Tiemann
- Ulrike Wehkamp
- Axel Hauschild
- Michael Weichenthal
- Jochen Utikal
Institutionen
- German Cancer Research Center(DE)
- Heidelberg University(DE)
- National Center for Tumor Diseases(DE)
- Dermatopathologie Friedrichshafen(DE)
- University Hospital Heidelberg(DE)
- University Hospital Regensburg(DE)
- Essen University Hospital(DE)
- RWTH Aachen University(DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin(DE)
- Universitätsklinikum Erlangen(DE)
- Charité - Universitätsmedizin Berlin(DE)
- Institut für Hämatopathologie Hamburg(DE)
- University of Mannheim(DE)
- University Hospital Schleswig-Holstein(DE)
- University Medical Centre Mannheim(DE)
- University of Lübeck(DE)